🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Follicular Lymphoma ( FL)

Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Follicular Lymphoma in Real World Study NCT05846763n/a1 site📍 Tianjin Institute of Hematology & Blood Diseases Hospital, China This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma NCT07121946Phase 16 sites📍 Duarte📍 St Louis📍 Buffalo LTZ Therapeutics, Inc. · Tests: LTZ-301, LTZ-301, LTZ-301 A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma NCT03460977Phase 185 sites📍 Tucson📍 Tucson📍 Tucson Pfizer · Tests: Mevrometostat (PF-06821497), Enzalutamide, Itraconazole Pirtobrutinib and Mosunetuzumab for the Treatment of Relapsed/Refractory Grades 1-3A Follicular Lymphoma, PROMOTE-FL Trial NCT06948786Phase 21 site📍 Seattle University of Washington · Tests: Pirtobrutinib, Mosunetuzumab, Biospecimen Collection, Biopsy Procedure, Computed Tomography Long-term Follow up Local Registry Study of Kymriah in South Korea NCT06785818n/a18 sites📍 Bundang Gu📍 Seongnam-si📍 Gyeonggi-do Novartis Pharmaceuticals · Tests: Tisagenlecleucel A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas. NCT06022029Phase 116 sites📍 Los Angeles📍 Tamarac📍 Canton OncoNano Medicine, Inc. · Tests: ONM-501, Cemiplimab Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) NCT07197307Phase 234 sites📍 Aachen📍 Augsburg📍 Berlin Universität Münster · Tests: Loncastuximab Tesirine and Epcoritamab Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader NCT05294731Phase 1, Phase 229 sites📍 Bengbu📍 Hefei📍 Beijing BeOne Medicines · Tests: Tacabrutideg Study to Evaluate the Response to Treatment With Mosunetuzumab in Relapsed/Refractory Follicular Lymphoma (FL) After at Least Two Lines of Therapy, Within the Compassionate Use Program (CUP). NCT07278921n/a1 site📍 Milan Andrés José Maria Ferreri · Tests: Mosunetuzumab Evaluate the Safety and Clinical Activity of HH2853 NCT04390737Phase 1, Phase 225 sites📍 Phoenix📍 Jacksonville📍 Rochester Haihe Biopharma Co., Ltd. · Tests: HH2853 Tablets Lenalidomide Combined With G-CHOP in the Treatment of Newly Diagnosed DLBCL With FL NCT06151080Phase 21 site📍 Xiamen The First Affiliated Hospital of Xiamen University · Tests: Lenalidomide combined with G-CHOP (LO CHOP) A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma NCT07562022Phase 31 site📍 Beijing Sinocelltech Ltd. · Tests: SCTB35 injection, Rituximab, Lenalidomide A Study of APG-3288 in Relapsed/Refractory Blood Cancers NCT07424833Phase 16 sites📍 Los Angeles📍 Jacksonville📍 Grand Rapids Ascentage Pharma Group Inc. · Tests: APG-3288 NexCAR19 (Talikabtagene Autoleucel) in Relapsed/Refractory B-Cell Malignancies (NexCAR19) NCT07502118Phase 2, Phase 34 sites📍 Ankara📍 Ankara📍 Ankara Health Institutes of Turkey · Tests: Talikabtagene Autoleucel Zanubrutinib Combined With G-CVP in Previously Untreated FL NCT06959732Phase 21 site📍 Beijing Cancer Institute and Hospital, Chinese Academy of Medical S… · Tests: zanubrutinib, obinutuzumab,combined with CVP Zanubrutinib in Combination With Obinutuzumab (ZO) for Newly Diagnosed Follicular Lymphoma NCT06553352Phase 21 site📍 Xiamen The First Affiliated Hospital of Xiamen University · Tests: Zanubrutinib combined with Obinutuzumab A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies NCT04830137Phase 116 sites📍 Duarte📍 Orange📍 San Francisco Nurix Therapeutics, Inc. · Tests: NX-2127 A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies NCT05131022Phase 162 sites📍 Duarte📍 San Francisco📍 Denver Nurix Therapeutics, Inc. · Tests: NX-5948 Optimizing ctDNA-based MRD Assessment in DLBCL, MCL, and FL Patients Undergoing CAR Therapy NCT05255354n/a1 site📍 Palo Alto Adaptive Biotechnologies · Tests: ClonoSEQ Epco, Zanu, Ritux for R/R FL or MZL NCT06563596Phase 23 sites📍 Boston📍 New York📍 Columbus Reid Merryman, MD · Tests: Zanubrutinib, Rituximab, Epcoritamab Comparison Between Local Radiotherapy Alone or Combined With Obinutuzumab in Early Stage Follicular Lymphoma: the GAZEBO Trial From the Fondazione Italiana Linfomi NCT05929222Phase 349 sites📍 Sassuolo📍 Alessandria📍 Avellino Fondazione Italiana Linfomi - ETS · Tests: Radiotherapy, Radiotherapy plus Obinutuzumab HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL NCT06792825Phase 21 site📍 Minneapolis Masonic Cancer Center, University of Minnesota · Tests: Tafasitamab, Rituximab, Lenalidomide A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies NCT07154823n/a13 sites📍 Iowa City📍 Bethesda📍 St Louis Tempus AI · Tests: None - Observational Study Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms NCT06043011n/a1 site📍 Freiburg im Breisgau iOMEDICO AG · Tests: Routine care as per site standard. A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma NCT06091254Phase 3190 sites📍 Tucson📍 Los Angeles📍 Orange Regeneron Pharmaceuticals · Tests: Odronextamab, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine Real-World Study to Assess Subcutaneous Epcoritamab in Adult Participants With Diffuse Large B-Cell and Follicular Lymphoma NCT06830759n/a73 sites📍 Ciudad Autonoma de Buenos Aire📍 Pilar📍 Ciudad Autonoma de Buenos Aire AbbVie A Real-world Study of Obinutuzumab-based Therapy for Previously Untreated FL NCT05899621n/a1 site📍 Shanghai Ruijin Hospital · Tests: Obinutuzumab, Lenalidomide, Bendamustine, Cyclophosphamide, Doxorubicin A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies NCT05780034Phase 19 sites📍 Denver📍 Sarasota📍 Chapel Hill Accutar Biotechnology Inc · Tests: AC676 Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma NCT07249905Phase 1, Phase 22 sites📍 Richmond📍 Nedlands ModeX Therapeutics, An OPKO Health Company · Tests: MDX2003 Zanubrutinib in Patients With Waldenström's Macroglobulinemia, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma and Follicular Lymphoma NCT05326308n/a2 sites📍 Salzburg📍 Lübeck iOMEDICO AG · Tests: Zanubrutinib, Obinutuzumab
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy